The diagnosis and management of familial amyloid polyneuropathy;Neuropathies amyloïdes familiales: Diagnostic et prise en charge

Revue Neurologique

Volumn 162, Issue 11, 2006, Pages 1138-1146

  Plante Bordeneuve V ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

Amyloidosis; Familial neuropathy; Genetics; Liver transplantation; Tranthyretin

Indexed keywords

ANTICONVULSIVE AGENT; APOLIPOPROTEIN A1; CLONAZEPAM; DOMPERIDONE; ERYTHROMYCIN; FLUDROCORTISONE; GELSOLIN; MIDODRINE; OCTREOTIDE; PREALBUMIN; TRICYCLIC ANTIDEPRESSANT AGENT;

AUTONOMIC NEUROPATHY; CLINICAL FEATURE; ELECTROPHYSIOLOGY; FAMILIAL AMYLOID POLYNEUROPATHY; GENE MUTATION; GENETIC COMPLEMENTATION; GENETIC COUNSELING; GENETIC EPIDEMIOLOGY; GENOTYPE PHENOTYPE CORRELATION; GEOGRAPHIC DISTRIBUTION; HUMAN; JAPAN; LIVER TRANSPLANTATION; MOLECULAR GENETICS; MORPHOLOGY; PATHOPHYSIOLOGY; PENETRANCE; PHENOTYPIC VARIATION; PORTUGAL; PROTEIN ANALYSIS; REVIEW; SENSORIMOTOR NEUROPATHY; SWEDEN;

EID: 33750691643     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(06)75130-x     Document Type: Review

References (50)

1. ADAMS D, SAMUEL D, GOULON-GOEAU C et al. (2000). The course and prognosis factors of familial amyloid polyneuropathy after liver transplantation. Brain, 123: 1495-1504.
2. ALMEIDA MR, ALVES IL, TERAZAKI H, SARAIVA MJ. (2000). Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy - TTR104H and TTRT119M. Biochem Biophys Res Commun, 270: 1024-1028.
3. ALMEIDA MR, MACEDO B, CARDOSO I et al. (2004). Selective binding to transthyretin and tetramer stabilisation in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem J, 381: 351-356.
4. ANDO Y. (2003). New therapeutic approaches for familial amyloidotic polyneuropathy (FAP). Amyloid, 10: 55-66.
5. ANDO Y, TERAZAKI H, NAKAMURA M et al. (2004). A different amyloid formation mechanism: de novo oculo leptomeningeal amyloid deposits after liver transplantation. Transpalntation, 77: 345-349.
6. ANDRADE C. (1952). A peculiar form of peripheral neuropathy. Brain, 75: 408-427.
7. ARAKI S, MAWATARI S, OHTA M, NAKAJIMA A, KUROIWA Y. (1968). Polyneuritic amyloidosis in a Japanese family. Arch Neurol, 18: 593-602.
8. AZOULAY D, SAMUEL D, CASTAING D et al. (1999). Domino liver transplant for metabolic disorders: experience with familial amyloid polyneuropathy. J Am Coll Surg, 189: 584-593.
9. BENSON MD. (1996). Leptomeningeal amyloid and variant transthyretins. Am J Pathol, 2: 351-354.
10. BERGETHON PR, SABIN M, LEWIS D, SWIMMS RW, COHEN AS, SKINNER M. (1996). Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation. Neurology, 47: 944-951.
11. BRETT M, PERSEY MR, REILLY MM et al. (1999) Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain, 122: 183-190.
12. CARVALHO F, SOUSA M, FERNANDES S, SILVA J, SARAIVA MJ, BARROS A. (2001). Preimplantation genetic diagnosis for familial amyloidotic polyneuropathy (FAP). Prenat Diagn, 21: 1093-1099.
13. GARCIA-HEROLA A, PRIETO M, PASCUAL S et al. (1999). Progression of cardiomyopathy and neuropathy after liver transplantation in a patient with familial amyloidotic polyneuropathy caused by tyrosine 77 transthyretin variant. Liver Transpl Surg, 5: 246-248.
14. HERLENIUS G, WILCZEK HE, LARSSON M, ERICZON BG. (2004). Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial amyloidotic polyneuropathy world transplant registry. Transplantation, 77: 64-71.
15. HOLMGREN G, STEEN L, EKSTEDT J, GROTH C, ERICZON BG. (1991). Biochemical effects of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP Met30). Clin Genet, 40: 242-246.
16. HOLMGREN G, ERICZON BG, GROTH CG et al. (1993). Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet, 341: 1113-1116.
17. IKEDA S, NAKAZATO M, ANDO Y, SOBUE G. (2002). Familial transthyretin-type amyloid polyneuropathy in Japan. Clinical and genetic heterogeneity. Neurology, 58: 1001-1007.
18. JACOBSON DR, MCFARLIN DE, KANE I, BUXBAUM JN. (1992). Transthyretin Pro, a variant asociated with early-onset agressive, diffuse amyloidosis with cardiac and neurologic involvement. Hum Genet, 89: 353-356.
19. JACOBSON DR, PASTORE RD, YAGHOUBIAN R et al. (1997). Variant-sequence transthyretin (isoleucine 122) in late onset cardiac amyloidosis in black americans. N Engl J Med, 13: 466-473.
20. KELLY JW. (1998). The alternative conformations of amyloidogebic proteins and their multi-step assembly pathways. Curr Op Struct Biol, 8: 101-106.
21. KOIKE H, MISU K, IKEDA S, ANDO Y et al. (2002). Type I (Transthyretin Met30) familial amyloid polyneuropathy in Japan: early-versus late onset form. Arch Neurol, 59: 1771-1776.
22. LACHMANN HJ, CHIR B, BOOTH DR et al. (2002). Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med, 346: 1786-1791.
23. MISU K, HATTORI N, NAGAMATSU M et al. (1999). Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain, 122: 1951-1962.
24. MISU K, HATTORI N, ANDO Y, IKEDA S, SOBUE G. (2000). Anticipation in early but not late-onset familial amyloid polyneuropathy (TTR-Met 30) in Japan. Neurology, 3: 451-452.
25. MUNAR-QUÈs M, PEDROSA JL, COELHO T et al. (1999). Two pairs of proven monozygotic twins discordant for familial amyloid neuropathy (FAP) TTR Met30. J Med Genet, 36: 629-632.
26. MUNAR-QUÈS M, SALVA-LADARIA L, MULET-PERERA P et al. (2000) Vitreous amyloidosis after liver transplantation in patients with familial amyloid polyneuropathy: ocular synthesis of mutant transthyretin. Amyloid, 4: 266-269.
27. MURPHY CL, EULITZ M, HRNCIC R et al. (2001). Chemical typing of amyloid protein contained in formalin-fixed paraffin embedded biopsy specimens. Am J Clin Pathol, 116: 135-142.
28. OLOFSSON BO, BACKMAN C, KARP K, SUHR OB. (2002). Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation, 73: 745-751.
29. PARRILLA P, RAMIREZ P, ANDREU LF et al. (1997). Long term results of liver transplantation in familial amyloid polyneuropathy type I. Transplantation, 64: 646-649.
30. PEPYS MB, HERBERT J, HUTCHINSON WL et al. (2002). Targeted pharmalogical depletion of serum amyloid P component for treatment of human amyloidosis. Nature, 417: 254-259.
31. PLANTÉ-BORDENEUVE V, LALU T, MISRAHI M, LACROIX C, ADAMS D, SAID G. (1998). Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy. Neurology, 51: 708-714.
32. PLANTÉ-BORDENEUVE V, CARAYOL J, FERREIRA A et al. (2003). Genetic study of transthyretin amyloid neuropathies. Carrier risks among French and Portuguese families. J Med Genet, 40: 120, 1-7.
33. REILLY MM, ADAMS D, BOOTH DR et al. (1995). Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy. Brain, 118: 849-856.
34. SAID G, ROPERT A, FAUX N. (1984). Length-dependent degeneration of fibers in Portuguese amyloid polyneuropathy: A clinicopathological study. Neurology, 34: 1025-1032.
35. SAID G. (2003). Familial amyloid polyneuropathy: mechanisms leading to nerve degeneration. Amyloid, 10: 7-12.
36. SARAIVA MJM. (2001a). Transthyretin amyloidosis: a tale of eak interactions. FEBS Lett, 498: 201-203.
37. SARAIVA MJM. (2001b). Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Human Mutation, 17: 493-503.
38. SOARES M, BUXBAUM J, SIRUGO G et al. (1999). Genetic anticipation in Portuguese kindredss with familial amyloidotic polyneuropathy is unlikely to be caused by triplet repeat expansions. Hum Genet, 104: 480-485.
39. SOUSA A, ANDERSSON R, DRUGGE U, HOLMGREN G, SANDGREN O. (1993). Familial amyloidotic polyneuropathy in Sweden: geographical distributionand age of onset, and prevalence. Hum Hered, 43: 288-294.
40. SOUSA A, COELHO T, BARROS J, SEQUEIROS J. (1995). Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-Type I in Povoa do Varzim and Vila do Conde (North of Portugal). Am J Hum Genet (Neuropsych Genet), 60: 512-521.
41. SOUSA MM, FERRAO J, FERNANDES R et al. (2004). Deposition and passage of transthyretin through the blood nerve barrier in recipients of familial amyloid polyneuropathy livers. Lab Invest, 84: 865-873.
42. STANGOU AJ, HEATON ND, HAWKINS PN. (2005). Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med, 352: 22.
43. STREGE RJ, SAEGER W, LINKE RP. (1998). Diagnosis and immunohistochemical classification of systemic amyloidosis. Virchows Arch, 433: 19-27.
44. SUHR O, HOLMGREN G, STEEN L et al. (1995). Liver transplantation in familial amyloidotic polyneuropathy. Follow up of the first 20 Swedish patients. Transplantation, 60: 933-938.
45. TANAKA K, YAMADA T, OHYAGI Y, ASAHARA H, HORIUSHI I, KIRA J. (2001). Suppression of transthyretin expression by ribozymes: a possible therapy for familial amyloidotic polyneuropathy. J Neurol Sci, 183: 79-84.
46. TASHIMA K, ANDO Y, TERAZAKI H et al. (1999). Outcome of liver transplantation for transthyretin amyloidosis: follow up of Japanese familial amyloidotic polyneuropathy patients. J Neurol Sci, 171: 19-23.
47. YAMASHITA T, ANDO Y, SUHR OB et al. (2000). A new diagnostic procedure to detect unknown transthyretin (TTR) mutations in familial amyloidotic polyneuropathy. J Neurol Sci, 173: 154-159.
48. YAZAKI M, TOKUDA T, NAKAMURA A et al. (2000). Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild type transthyretin. Biochem Biophys Res Commun, 274: 702-706.
49. YAZAKI M, YAMASHITA T, KINCAID JC et al. (2002). Rapidly progressive amyloid polyneuropathy associated with a novel variant transthyretin serine 25. Muscle Nerve, 25: 244-250.
50. YAZAKI M, LIEPNIEKS JJ, KINCAID JC, BENSON MD. (2003). Contribution of wild type tranthyretin to hereditary peripheral nerve amyloid. Muscle Nerve, 28: 438-442.